April 5, 2017
Sen. Tom Cotton, R-Ark., is one of three GOP senators seeking an investigation into six-figure annual costs for drugs intended to treat rare diseases. Photo Credit: Alex Brandon/AP
The U.S. Government Accountability Office (GAO) will investigate potential abuse of the O...
Meet with us at the 38th annual J.P. Morgan Healthcare Conference, January 13-16, 2020
December 2, 2019
Meet with us at the RARE Patient Advocacy Summit, September 18-20, 2019
August 15, 2019
Meet with us at the 37th annual J.P. Morgan Healthcare Conference, January 6-9, 2019
November 16, 2018
Meet with us at the 8th annual World Orphan Drug Congress in Washington, D.C., April 25-27, 2018
April 19, 2018
Meet with us at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco January 8-11, 2018
November 13, 2017
Diligentia President, Joff Masukawa, will serve as a panelist at the Virginia Bioscience Commercialization Luncheon
October 22, 2017
Diligentia President, Joff Masukawa, will serve as a panelist in this evening's Johns Hopkins University debate on Universal Healthcare in the US
June 1, 2017
What Does the Government Investigation on the Orphan Drug Program Mean for Drug Manufacturers?
The Impact of the American Health Care Act on Rare Disease Patients
March 20, 2017
What Does The Scrutiny on Orphan Drug Pricing Mean For Manufacturers and Consumers?
March 13, 2017